Section of Cardiology, Veterans Affairs Medical Center, Salem, VA, USA.
Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Curr Cardiol Rep. 2018 Oct 26;20(12):142. doi: 10.1007/s11886-018-1075-7.
Advancements in cancer treatment have resulted in improved cancer-related survival and consequently an increase in the number of cancer survivors. Unfortunately, associated with this increase in cancer-related survivorship, cardiac events have occurred with increasing frequency in cancer survivors. Recognition that cancer survivors are at increased risk for cardiovascular (CV) morbidity has generated interest to develop cardiac imaging techniques that identify subclinical CV disease during receipt of potentially cardiotoxic cancer treatment. Since subclinical cardiovascular disease precedes future cardiac events, early recognition of subclinical CV disease during receipt of potentially cardiotoxic cancer treatment offers the opportunity to initiate strategies that prevent further evolution of subclinical CV disease as well as cardiac events.
Cardiovascular magnetic resonance imaging (CMR) is an advanced imaging technique that identifies imaging markers of subclinical cardiovascular disease in patients receiving potentially cardiotoxic cancer treatment regimens. In this article, we review the use of CMR for identifying subclinical cardiac disease in patients receiving potentially cardiotoxic cancer treatment regimens. The ability of contemporary CMR to accurately define cardiac anatomy, function, and tissue characteristics may represent a critical tool to assess patients with cancer.
癌症治疗的进步导致癌症相关生存率提高，因此癌症幸存者的数量也随之增加。不幸的是，随着癌症相关生存人数的增加，癌症幸存者中心血管事件的发生频率也在增加。认识到癌症幸存者患心血管（CV）疾病的风险增加，促使人们开发心脏成像技术，以在接受潜在致心脏病的癌症治疗期间识别亚临床 CV 疾病。由于亚临床心血管疾病先于未来的心脏事件，因此在接受潜在致心脏病的癌症治疗期间早期识别亚临床 CV 疾病为预防亚临床 CV 疾病以及心脏事件的进一步发展提供了机会。
心血管磁共振成像（CMR）是一种先进的成像技术，可识别接受潜在致心脏病的癌症治疗方案的患者的亚临床心血管疾病的影像学标志物。在本文中，我们回顾了 CMR 在识别接受潜在致心脏病的癌症治疗方案的患者中的亚临床心脏疾病中的应用。当代 CMR 准确定义心脏解剖结构、功能和组织特征的能力可能代表评估癌症患者的重要工具。
